Protoporphyrin IX (PpIX)-conjugated self-lighting nanoparticles for photodynamic therapy: synthesis and characterization

Published on May 4, 2015   35 min

Other Talks in the Series: Nanomedicine

0:00
Hello, everybody. My name is Homa. I'm a post-doc research associate in the chemical engineering department at Northeastern University in Boston where my today talk is going to cover my PhD thesis which was about protoporphyrin IX conjugated self-lighting nanoparticle for photodynamic therapies in synthesis and characterization. This research was done in joint biomedical engineering program in the University of Texas at Arlington and University of Texas Southwestern Medical Center in Dallas under supervision of Professor Wei Chen from the Department of Physics in the University of Texas at Arlington.
0:45
The reason we focused on cancer during this research was that cancer is the second leading cause of death in the United States. Cancer statistics of the United States in 2010 and 2012 confirm more than one and half a million new cancer cases, and more than half a million deaths. Cancer is a term used for diseases in which abnormal cells develop without control and are able to invade other tissues. Cancer cells can spread to other parts of the body through the blood and lymph system. When a tumor becomes malignant, then it becomes cancer.
Hide

Protoporphyrin IX (PpIX)-conjugated self-lighting nanoparticles for photodynamic therapy: synthesis and characterization

Embed in course/own notes